文献速递乳腺癌

氟维司群联合哌柏西利或安慰剂治疗内分泌敏感、激素受体阳性/HER2阴性晚期乳腺癌的随机II期研究:GEICAM/2014-12(FLIPPER)

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
PubMed 文献 · Eur J Cancer · 2021-12-11

这项随机双盲II期研究纳入189例内分泌敏感的HR阳性/HER2阴性晚期乳腺癌绝经后女性,比较哌柏西利联合氟维司群与安慰剂联合氟维司群一线治疗。哌柏西利组1年无进展生存率为83.5%,安慰剂组为71.9%(HR 0.55,80% CI 0.36-0.83,P=0.064);中位无进展生存期分别为31.8个月和22.0个月(aHR 0.48,80% CI 0.37-0.64,P=0.001)。

要点

  • 哌柏西利联合氟维司群组1年PFS率为83.5%,安慰剂联合氟维司群组为71.9%(HR 0.55,80% CI 0.36-0.83,P=0.064)。
  • 哌柏西利组中位PFS为31.8个月,安慰剂组为22.0个月(aHR 0.48,80% CI 0.37-0.64,P=0.001)。
  • 哌柏西利组最常见3-4级不良事件为中性粒细胞减少(68.1% vs 0%)、白细胞减少(26.6% vs 0%)。

核心结论

  • 在HR阳性/HER2阴性内分泌敏感的晚期乳腺癌患者中,哌柏西利联合氟维司群较安慰剂联合氟维司群显示出更好的1年PFS率和中位PFS。

研究设计与样本

  • 随机(1:1)、双盲、II期研究,纳入绝经后HR阳性/HER2阴性晚期乳腺癌女性,为新发转移或辅助内分泌治疗>12个月后复发者。
  • 计划样本量190例,实际随机189例:哌柏西利/氟维司群组94例,安慰剂/氟维司群组95例。
  • 分层因素为复发 vs 新发转移和内脏受累;主要终点为1年无进展生存率。

主要发现

  • 哌柏西利/氟维司群组1年PFS率为83.5%,安慰剂/氟维司群组为71.9%(HR 0.55,80% CI 0.36-0.83,P=0.064)。
  • 哌柏西利/氟维司群组中位PFS为31.8个月,安慰剂/氟维司群组为22.0个月(aHR 0.48,80% CI 0.37-0.64,P=0.001)。
  • 3-4级不良事件:中性粒细胞减少哌柏西利/氟维司群组68.1% vs 安慰剂/氟维司群组0%,白细胞减少26.6% vs 0%,贫血3.2% vs 0%,淋巴细胞减少14.9% vs 2.1%。
  • 最常见的非血液学3-4级不良事件为乏力,哌柏西利/氟维司群组4.3% vs 安慰剂/氟维司群组0%。

关键数值与推荐

  • 样本量190例,双侧α=0.2,80%把握度,假设哌柏西利/氟维司群组和安慰剂/氟维司群组PFS率分别为0.695和0.545。
  • 45.5%的患者为新发转移性疾病,60.3%的患者有内脏受累。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative endocrine-sensitive advanced breast cancer (ABC) patients remains uncharacterized. PATIENTS AND METHODS: In this randomized (1:1), double-blind, phase II study, postmenopausal women with HR-positive, HER2-negative ABC with de novo metastatic disease or those who relapsed after >12 months of adjuvant endocrine therapy received palbociclib/fulvestrant or placebo/fulvestrant. Stratification was based on recurrent versus de novo metastatic disease and visceral involvement. The primary objective was one-year progression-free survival (PFS-1y) rate. The sample size was 190 patients. The two-sided alpha of 0.2, 80% of power to detect a difference between the arms, assuming PFS rates of 0.695 and 0.545 for palbociclib/fulvestrant and placebo/fulvestrant, respectively. RESULTS: In total, 189 patients were randomized to palbociclib/fulvestrant ([n = 94] or placebo/fulvestrant [n = 95]). 45.5% and 60.3% of patients had de novo metastatic disease and visceral involvement, respectively. PFS-1y rates were 83.5% and 71.9% in the palbociclib/fulvestrant and placebo/fulvestrant arms, (HR 0.55, 80% CI 0.36-0.83, P = 0.064). The median PFS were 31.8 and 22.0 months for the palbociclib/fulvestrant and placebo/fulvestrant arms (aHR 0.48, 80% CI 0.37-0.64, P = 0.001). The most frequent grade 3-4 adverse events were neutropenia (68.1% vs. 0%), leucopenia (26.6% vs. 0%), anemia (3.2% vs. 0%), and lymphopenia (14.9% vs. 2.1%) for the palbociclib/fulvestrant and placebo/fulvestrant, respectively. The most frequent non-hematologic grade 3-4 adverse event was fatigue (4.3% vs. 0%). CONCLUSIONS: Palbociclib/fulvestrant demonstrated better PFS-1y rates and median PFS than placebo/fulvestrant in HR-positive/HER2-negative endocrine-sensitive ABC patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Albanell J, Martínez MT, Ramos M, et al. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). Eur J Cancer. 2021. PMID: 34902765. doi:10.1016/j.ejca.2021.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。